272.F Mabion SA
- Market cap
- EUR 27.0M
- P/E
- -
- P/B
- 4.93x
- ROE
- -204.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 272.F undervalued?
Graham numberThe Graham number of Mabion SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mabion SA fundamental analysis
No fundamental analysis for Mabion SA yet.
Mabion SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mabion SA
Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.
Full company profileMabion SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mabion SA annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 56.9M | 164M | 152M | 69.0M | 15.8M | 15.7M |
| Gross Profit | 35.9M | 66.0M | 115M | 41.2M | -17.4M | -12.5M |
| Operating Income | -6.93M | 26.5M | 68.5M | -1.13M | -50.4M | -39.7M |
| EBITDA | - | 32.7M | 58.1M | 10.1M | -52.8M | -38.1M |
| Net Income | 1.90M | 23.2M | 41.3M | -6.33M | -62.6M | -49.4M |
| EPS | 0.12 | 1.43 | 2.55 | -0.39 | -3.87 | -3.05 |
| Balance Sheet | ||||||
| Total Assets | 184M | 186M | 208M | 159M | 110M | 102M |
| Total Liabilities | 131M | 110M | 90.5M | 48.0M | 61.6M | 78.1M |
| Shareholders' Equity | 53.3M | 76.5M | 118M | 111M | 48.8M | 24.2M |
| Cash & Short-term Investments | 48.7M | 53.6M | 47.8M | 38.4M | 6.37M | 5.80M |
| Cash Flow | ||||||
| Operating Cash Flow | -32.9M | 38.8M | -2.33M | 39.9M | -41.6M | -37.1M |
| Capital Expenditure | 31.6M | 16.7M | 38.0M | 12.3M | 892K | 1.64M |
| Free Cash Flow | -64.5M | 22.1M | -40.3M | 27.5M | -42.5M | -38.7M |
| Ratios | ||||||
| ROE | 3.6% | 30.3% | 35.0% | -5.7% | -128.2% | -204.3% |
| ROA | 1.0% | 12.5% | 19.8% | -4.0% | -56.7% | -48.3% |
| Net Profit Margin | 3.3% | 14.1% | 27.2% | -9.2% | -397.4% | -315.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Mabion SA dividends
Mabion SA has not paid dividends in the last 5 fiscal years.
Who owns Mabion SA
- Insiders 28.98%
- Institutions 0.00%
- Public & others 71.02%
- Shares outstanding 16.2M
- Free float 11.5M
Mabion SA company profile
- Company name
- Mabion SA
- Ticker
- 272.F
- ISIN
- PLMBION00016
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 199
- Fiscal year end
- December
- Address
- Medical Biotechnology Scientific and Industrial Complex, Konstantynów Lódzki, Poland, 95-050
- Phone
- 48 42 207 7890
- Website
- mabion.eu
About Mabion SA
Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.
Mabion SA management
7- Mr. Gregor KawaletzCEO & President of the Management Board
- Ms. Julita Balcerek M.D.Chief Operating Officer
- Mr. Detlef BehrensChief Business Affairs Officer & Member of the Management Board
- Mr. Joaquin Santos BenitoChief Transformation Officer & Member of the Management Board
- Pawel PobiedzinskiHead of Logistics & Procurement
- Ms. Joanna KrolasikHead of Microbiology Division
- Paulina TobolaHead of Analytics Development Department